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Abstract

Go to:

Within T-cell-dependent germinal centers, p53 gene transcription is repressed by Bcl-6 and is thus less
vulnerable to mutation. Malignant lymphomas within inflamed extranodal sites exhibit a relatively high
incidence of p53 mutations. The latter might originate from normal B-cell clones manifesting activationinduced cytosine deaminase (AID) and up-regulated p53 following T-cell-independent (TI) stimulation.
We here examine p53 gene transcription in such TI clones, with a focus on modulatory effects of
prostaglandin E2 (PGE2), and evaluate progeny for p53 mutations. Resting IgM+IgD+CD27− B cells from
human tonsils were labeled with CFSE and stimulated in vitro with complement-coated antigen surrogate,
IL-4, and BAFF ± exogenous PGE2 (50 nM) or an analog specific for the EP2 PGE2 receptor. We use flow
cytometry to measure p53 and AID protein within variably divided blasts, qRT-PCR of p53 mRNA from
cultures with or without actinomycin D to monitor mRNA transcription/stability, and single-cell p53 RTPCR/sequencing to assess progeny for p53 mutations. We report that EP2 signaling triggers increased p53
gene transcriptional activity in AID+ cycling blasts (P<0.01). Progeny exhibit p53 mutations at a
frequency (8.5×10−4) greater than the baseline error rate (<0.8×10−4). We conclude that, devoid of the
repressive influences of Bcl-6, dividing B lymphoblasts in inflamed tissues should display heightened p53
transcription and increased risk of p53 mutagenesis.—Haque, S., Yan, X. J., Rosen, L., McCormick, S.,
Chiorazzi, N., Mongini, P. K. A. Effects of prostaglandin E2 on p53 mRNA transcription and p53
mutagenesis during T-cell-independent human B-cell clonal expansion.
Keywords: B lymphocyte, TP53, eicosanoid, inflammation, lymphoma
B-lymphocyte immune responses are characterized by clonal proliferation and accompanying DNA
damage, due to rising reactive oxygen species (ROS) and activation-induced cytosine deaminase (AID).
The above stresses are expected to alert p53, the “guardian of the genome,” through p53 post-translational
modifications (1). While a p53 response is activated during formation of T-cell-dependent (TD) germinal
centers (GCs), the response is muted relative to the extent of DNA damage. This, in part, reflects strong
repression of the p53 gene by Bcl-6, the GC master regulator (2, 3). Notably, because transcriptionally
active genes are favored targets for mutagenic agents (4,–7), repression likely thwarts p53 mutagenesis
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during formation of most B-cell memory, potentially explaining why p53 mutations are rare within TD
mouse Peyer's patch B cells (8) and relatively infrequent in human GC-derived B-cell malignancies (2, 9).
Proliferative responses of shorter duration with little up-regulation of Bcl-6 are induced by T-cellindependent (TI) stimuli. TI B-cell clonal expansion occurs in extrafollicular sites (10,–13) and is elicited
within the splenic marginal zone (MZ) and inflamed peripheral tissues expressing antigen (e.g., microbes
and apoptotic cells), costimuli from the innate immune system [including complement (C3), IL-4, IL-13,
BAFF, and APRIL], and TLR ligands (14,–21). The lesser clonal expansion seen in TI responses, in part,
reflects p53 activity. B cells from p53-deficient mice cycle more rapidly than wild-type B cells on
stimulation with B-cell antigen receptor (BCR) ligand and IL-4 (22, 23). In addition, this laboratory
demonstrated that p53 protein is up-regulated and functional in promoting the death of B-cell progeny
generated in response to C3d-coated multivalent Ag, IL-4, and BAFF (24). Splenic MZ hypertrophy in
p53-deficient mice that resist early malignancies (25) is consistent with this p53 function in vivo.
Accruing evidence suggests that compromised p53 axis function promotes development of non-GC B-cell
malignancies. MZ lymphoma is the major B-cell malignancy to emerge from p53-deficient mice without
additional genetic alterations (25). Furthermore, mice with B-cell-selective p53 deletion show frequent
pre-GC B-cell lymphomas, including those of MZ derivation (26, 27). In addition, in humans, B-cell p53
mutations are relatively common in malignancies of non-GC origin, e.g., MZ lymphoma, mucosaassociated lymphoid tissue lymphoma, and B-cell chronic lymphocytic leukemia (B-CLL) (9, 28,–33).
These observations suggest that during TI immune responses, the p53 gene is more vulnerable to mutation,
and furthermore, cells with certain p53 mutations undergo positive selection.
This laboratory's extensive study of the cellular changes accompanying a dynamic clonal
expansion/contraction of normal human B cells as they respond to C3d antigen, IL-4, and BAFF (24, 34,–
36) suggests that the latter clones are particularly prone to p53 mutation. DNA-modifying AID is highly
expressed during division of these TI-activated B-cell clones (35); the robust, albeit short-lived,
proliferative burst likely generates mutagenic ROS (24), and the B cells lack direct T-cell contacts needed
for up-regulation of Bcl-6 (2) and high-fidelity DNA repair enzymes (37). Furthermore, replicating blasts
express elevated levels of cyclooxygenase (COX-2), the downstream PGE2 synthase, mPGES-1, and the
adenylate cyclase-activating PGE2 receptor EP2 (34, 35). It is important to note that COX-2 inhibitor
treatment reduces AID expression, and, furthermore, exogenous PGE2 augments AID levels (35),
suggesting a mechanism for AID amplification in inflamed tissues.
The present study examines whether the p53 gene is transcriptionally active within replicating
lymphoblasts of this TI response and whether PGE2 signals influence p53 gene transcription and
mutagenesis. This was deemed important because inflamed tissues are sites where p53-mutated B cell
malignancies are often detected (30, 31, 33, 38,–41).

MATERIALS AND METHODS

Go to:

Resting follicular (FO) human B cells
Deidentified tonsils from elective tonsillectomy were obtained according to Institutional Review Board
guidelines (with cooperation of the Departments of Pathology at New York Eye and Ear Infirmary, New
York, NY, USA, and North Shore University Hospital, Manhasset, NY, USA). Methods detailed elsewhere
(24, 35, 36) were used to purify a minority of resting FO B cells (high density CD27−, CD43−, CD19+,
IgM+, IgD+) from tonsils for subsequent in vitro activation.
Reagents for cell culture
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B cells were activated by culture with polyclonally activating surrogate for C3dg-coated, moderately
multivalent antigen [dextran with covalently conjugated anti-human IgM and anti-human CD21
(BCR:CD21-L)], and human rIL-4 and rBAFF, as described previously (34, 36). These conditions induce
virtually all resting B cells to express CD27 and CD86, while typically only a fraction undergo division
(36).
B-cell activation
Resting B cells were cultured in an enriched RPMI 1640-based medium, optimized for growth (36). To
monitor divisions, purified B cells were prelabeled with carboxyfluorescein succinimidyl ester (CFSE) as
described previously (36) and cultured at 105 cells/200 μl in 96-well plates (for staining of activated blasts)
or 106 cells/2 ml in 24-well plates for experiments involving lysates, RNA extraction, and sorting of single
cells for p53-specific RT-PCR. PGE2/butaprost was pulsed on d 2 and 4 or d 4 only, as indicated. Stocks of
PGE2 and butaprost (Cayman Chemical, Ann Arbor, MI, USA) in ethanol were stored at −80°C and
diluted before use. Culture harvest was generally on d 5. In some experiments, pan-caspase inhibitor, ZVAD-FMK (Sigma-Aldrich, St. Louis, MO, USA; 40 μM final) was added at d 3 to reduce activationinduced cell death (24). Alternatively, actinomycin D (Sigma-Aldrich; 5 μM final) was added to inhibit
RNA polymerase (42).
Intracellular staining
Previously described methods for staining of p53, AID, and pH2AX (24, 35) within CFSE-lymphoblasts
were employed and involved PE-anti-p53 (DO-7; BD Pharmingen, San Diego, CA, USA), PE-IgG2b mAb
control (27–35; BD Pharmingen), mouse anti-AID mAb (ZA-001; Invitrogen, Carlsbad, CA, USA), and
anti-pH2AX-Ser-139/140 (3F2; Thermo Scientific, Waltham, MA, USA) or IgG isotype controls, followed
by PE-conjugated anti-IgG Ab.
Semiquantitative analysis of p53 mRNA
Total RNA was extracted from 1–5 × 106 cells using the Qiagen Miniprep kit (Qiagen, Gaithersburg, MD,
USA) with cDNA synthesis performed using Oligo-dT primers (Invitrogen kit). PCR amplification
involved the following primers: p53(A), forward 5-cagccagactgccttccg-3 and reverse 5gcaagtcacagacttggctg-3, yielding 400-bp amplicon (exons 2a, 3, and 4); and β-actin, forward 5′gtcctctcccaagtccacaca-3′ and reverse 5′-ctggtctcaagtcagtgtacaggtaa-3′. PCR parameters were 95°C for 30 s,
58°C for 60 s, and 72°C for 30 s for 35 cycles in a total volume of 30 µl. PCR products were resolved as
described previously (24, 35).
Quantitative PCR (qPCR)
qPCR (TaqMan; Applied Biosystems, Foster City, CA, USA) of cDNA was performed (24) using the
following primers and probes: p53, forward 5-aggccttggaactcaaggat-3 and reverse 5-ccctttttggacttcaggtg-3,
UPL probe 12 (accession no. NM_001126114.1); and β-actin, forward 5′-ccaaccgcgagaagatga-3′ and
reverse 5′-ccagaggcgtacagggatag-3′, UPL probe 64 (accession no. NM_001101.3). Probes were obtained
from human universal probe library of Roche Applied Science (Indianapolis, IN, USA). qPCR involved
triplicates or quadruplets of cDNA template and Eurogentec master mixes (AnaSpec, Fremont, CA, USA)
with parameters as reported previously (24). Amplification was extended to 45 cycles to reveal the plateau
of maximal substrate use; threshold cycle (Ct) values for data analysis represented thresholds within the
linear region (routinely between 20 and 35). Fold change was calculated by comparing treated vs.
untreated groups; analysis by RQ Manager 1.2 (Applied Biosystems). The reference gene β-actin was used
as endogenous control, except in the supplemental experiments.
Single-cell p53-specific RT-PCR
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On d 5–6, activated cultures were harvested, washed with cold PBS, and resuspended in PBS + 3% FCS.
Single cells were sorted (FACS-Aria; BD Biosciences, San Jose, CA, USA) and individually deposited in
each well of a 96-well PCR plate into 4.0 μl cell lysis buffer (0.5× PBS and 0.01 M DTT, Invitrogen; 2.0
U/μl RNAsin (verde) inhibitor, Promega, Madison, WI, USA; 0.25 U/μl PrimRNAse Inhibitor, Qiagen;
and molecular grade water). Single lysed cells were rapidly frozen on dry ice. At the time of cDNA
preparation, lysates were defrosted on ice, and 3.5 μl buffer (42.8 ng/μl random hexamer primers,
Invitrogen; 1.43% Nonidet P-40, Sigma-Aldrich; 0.25 U/μl PrimRNAse Inhibitor, Qiagen; and molecular
grade water) was added to each PCR-plate well and incubated at 65°C for 1 min. Plates were spun quickly
at 4°C and placed on ice. To each well. 7.0 μl buffer (2.1× FS buffer from cDNA kit, Invitrogen; 0.014 M
DTT, Invitrogen; 1.79 mM dNTPs, Invitrogen; 0.6 U/μl RNAsin (verde) inhibitor, Promega; 0.14 U/μl
PrimRNAse Inhibitor, Qiagen; 7.1 U/μl RT-Superscript III, Invitrogen; and molecular grade water) was
added. The PCR plate was tapped gently, centrifuged, and placed on a PCR thermal cycler (MJ Research,
St. Bruno, QC, Canada; DNA Engine Dyad, Bio-Rad, Richmond, CA, USA) at 42°C for 5 min, 25°C for
10 min, 40°C for 60 min, 95°C for 5 min, and 4°C thereafter.
PCR amplification of single-cell p53 cDNA for mutation analysis
Two rounds of PCR (at 35 cycles) amplified p53 cDNA from each cell. In the first round, 1.0 μl cDNA
was used as template and Hot-Start Taq (Qiagen) was used instead of Ampli-Taq Gold (Invitrogen). In the
second round, 2 μl amplicon (from first round) was used as template iwith Ampli-Taq Gold. The running
procedure for semiquantitative PCR (above) was employed. Primers were p53(A) primers (above), which
amplified p53 exons 2a, 3, and 4 (tonsils T602, T606, T612, and T613), and p53Ex4 primers, which
amplified p53 exon 4 only (T587 and T597): forward 5′-cttgccgtcccaagcaatc-3′ and reverse 5gcaagtcacagacttggctg-3, yielding a 270-bp amplicon.
PCR amplicon cleaning and p53 sequence analysis
Electrophoresis-tested p53+ amplicons were cleaned with the QIAquick PCR purification kit (Qiagen), and
comparable amounts were sequenced by Genewiz (South Plainfield, NJ, USA). Each sample was
sequenced with forward and reverse primers separately. Data were analyzed by ChromasPro and Chromas
Lite software (Technylesium Pty. Ltd., South Brisbane, QLD, Australia).
Statistics
For experiments comparing p53 mRNA half-life in cultures with or without PGE2 and actinomycin D, a
linear mixed model compared the mean fold change between PGE2+ and PGE2− cultures and respective
controls across time (30 min and 1, 3, 8, and 20 h after actinomycin D). The interaction term between
group and time assessed whether slopes in PGE2+ and PGE2− cultures were different. If the interaction
term was nonsignificant, it was removed from the final model. A mixed models approach accounted for
the repeated measurements over time within an experiment. For experiments comparing p53 mutation
incidence in PGE2+ and PGE2− cultures, a generalized linear mixed model with a logit link was employed.
(While a mixed models approach accounted for multiple measurements within an experiment with a single
donor, results did not differ qualitatively, leading to the assumption of independence between
observations.) Analyses were conducted in 2 ways: with the unit analysis as total nucleotides screened
(mutation frequency/base pair), and with the unit analysis as total cells screened (mutation frequency/cell).
Mutation frequency between variably treated cultures was compared using the χ2 test or Fisher's exact test.
In the cases when the frequency of total observed mutations between 2 differing nucleotide motifs was
compared, the total number of available sites with each motif within the p53 sequences analyzed was taken
into account. A χ2 analysis or Fisher's exact test was used to determine whether mutations favored one
motif over another. Other statistical methods are indicated in figure legends.
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC3898655/?report=printable
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RESULTS

Go to:

During human B-cell TI clonal expansion, maximal p53 protein expression precedes
maximal AID protein
Consistent with past immunoblotting and flow cytometric studies of this laboratory (24, 35), Fig. 1A
shows that both p53 and AID protein rise in a division-linked manner following the activation of resting
follicular B cells from human tonsils with BCR:CD21-L, IL-4, and BAFF. The present simultaneous
assessment of both proteins in the same experiments shows that p53 reaches maximal expression at earlier
divisions than AID (Fig. 1B) and suggests that AID-induced DNA damage, and ensuing p53 protein
stabilization, do not solely explain the elevation in p53 protein.
TI B lymphoblasts manifest elevated p53 mRNA
Transcription of p53 is reported to rise prior to proliferation (within 6 h) following human B-cell activation
with anti-IgM and growth factors (43). We were interested in determining whether p53 transcription
remains high during a TI B-cell proliferative response characterized by high AID expression (35). To do
so, p53 mRNA levels in freshly isolated naive B cells were compared with that in proliferating cultures on
d 4 following TI activation. Semiquantitative PCR (Fig. 2A) and qPCR (Fig. 2B) show that p53 RNA
levels are notably elevated at this activation interval. Because not all CD86+, CD27+ B lymphoblasts
uniformly divide in these cultures (36), we examined whether blasts representing 0 and 3–4 divisions differ
in p53 mRNA expression. Viable CFSE-labeled blasts were sorted according to division status, and cDNA
was assessed by qPCR (Fig. 2C). Notably, blasts representing 3–4 divisions display significantly greater
p53 mRNA than undivided blasts (P=0.006). Virtually all of these divided blasts express elevated AID
protein (Fig. 1A and ref. 35).
Exogenous PGE2 significantly augments p53 mRNA within dividing B lymphoblasts
One notable characteristic of cycling B lymphoblasts is an increase in COX-2 and linked proteins (34, 35,
44). The elevated p53 mRNA levels in cycling blasts and evidence of substantial crosstalk between the p53
and COX-2/PGE2 axes in other cells (45,–50) led us to examine whether PGE2 signaling influences p53
expression. For these experiments, exogenous PGE2 (50 nM), or vehicle alone, was pulsed into d 4
activated B cell cultures, and p53 RNA levels were subsequently assessed by qPCR. Following an early
insignificant decline, PGE2-pulsed cultures showed significantly greater p53 mRNA than controls, with
the peak increase at 8 h following PGE2 (P=0.0004; Fig. 3A, B). The PGE2-mediated increase was noted,
regardless of whether β-actin, GAPDH, RPS20, RPS13, or RPL27 was used as housekeeping reference
gene (ref. 51 and Supplemental Fig. S1). Interestingly, a comparison of undivided and divided blasts from
the same cultures for sensitivity to this PGE2 effect (Fig. 3C) showed that divided blasts uniquely
displayed PGE2-boosted p53 mRNA.
The effects of PGE2 on p53 protein appear to be considerably more complex, as might be expected, given
the many mechanisms for post-translational regulation of p53 following cell stress and DNA damage (52).
Dividing d 5 lymphoblasts display significantly greater levels of p53 protein when cultures are exposed to
PGE2, ranging from 10 to 1000 nM, on d 2 and 4 after TI activation (Supplemental Fig. S2). Nevertheless,
if TI-activated cultures receive a similar pulse with PGE2 solely on d 4, p53 protein levels reproducibly
decline by 24 h (data not shown). Additional work is needed to define the mechanisms involved. Given the
rising expression of adenylate cyclase-activating PGE2 receptors in cycling B cells (35), the drop in p53
protein following an acute pulse with p53 on d 4 may involve cAMP-facilitated Mdm2 ubiquitination of
p53 protein (53).
Selective EP2 agonist promotes p53 mRNA expression
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC3898655/?report=printable
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We were interested in assessing whether the PGE2-driven increase in p53 mRNA involved EP2, the PGE2
receptor that increases most significantly with successive divisions (ref. 35 and Fig. 4A). This was
accomplished through testing the effects of a structural analog of PGE2 that is highly selective for EP2,
butaprost. Figure 4B shows that d 4 activated cultures pulsed with butaprost from 2 to 30 h earlier express
significantly greater levels of p53 mRNA than vehicle-pulsed cultures. The dose response in Fig. 4C is
consistent with butaprost's significantly lesser affinity for EP2, as compared to PGE2 (54).
PGE2 promotes increased p53 mRNA transcription but not greater mRNA stability
A series of experiments was performed to discern whether the PGE2-mediated boost in p53 mRNA was
explained by effects on transcription and/or mechanisms that stabilize message (55,–57). As a first step, we
asked whether RNA polymerase activity is needed for sustained p53 mRNA levels in proliferating d 4
cultures. Figure 5 shows that this is so: p53 mRNA levels dropped significantly following 8 h exposure to
actinomycin D. In addition, treatment with actinomycin D just prior to the PGE2 pulse abrogates the
PGE2-induced increase in p53 mRNA.
While the above results indicate that p53 transcription is required during the postpulse period, the PGE2mediated boost might reflect effects on mRNA stability, rather than transcription. To address this, mRNA
decay rates were compared in PGE2-pulsed and parallel nonpulsed cultures, beginning at 8 h after the
pulse (Fig. 6). Any new transcription was blocked by treatment with actinomycin D. Pooled values from 4
replicate experiments show that the half-life of p53 message is ∼8 h. Notably, the decay rates (slope of
plots over time) in PGE2+ and PGE2− cultures were not statistically different (Fig. 6). Thus, PGE2 does not
promote greater p53 mRNA stability.
Unexpectedly, p53 mRNA levels in actinomycin D-treated PGE2+ cultures were consistently lower than
those in parallel PGE2− cultures. This was most evidenced early after the block in RNA synthesis (Fig. 6).
One possibility is that PGE2-induced signals concomitantly enhance synthesis of negative regulators of
p53 transcript stability, e.g., miR125a and miR125b (58), but further experiments are needed to resolve
this.
Single-cell p53 RT-PCR shows that PGE2 signals heighten the frequency of dividing
lymphoblasts with detectable p53 mRNA
Single-cell p53-specific RT-PCR analyses were initiated for the purpose of discerning whether PGE2
increases the proportion of cells with a transcriptionally active p53 gene or whether it uniformly elevates
p53 mRNA transcription in all cells. Figure 7A shows representative results from the PCR amplification
of p53 and β-actin cDNA from 56 sorted individual B-cell progeny from TI cultures with or without PGE2.
While ∼90% of the wells containing a single B cell scored positive for β-actin, the frequency of p53+ wells
was notably lower, indicating that individual progeny vary in their level of p53 transcripts. Of interest, the
exogenous PGE2 pulse notably augmented the proportion of p53+ single cells (Fig. 7B). This PGE2boosting effect was observed in each of 6 total experiments and was highly significant (P<0.001; Fig. 7C).
Thus, PGE2 clearly amplifies the proportion of B lymphoblasts producing relatively high levels of p53
mRNA. Since a threshold level of p53 mRNA may be necessary for p53 amplification (detection), we
cannot exclude the possibility that PGE2 positively influences p53 mRNA transcription in all progeny.
Multiple alternatively spliced transcripts of p53 are reported (59). Because identification of p53 mRNA+
cells in Fig. 7 involved primers for exons 2 and 4, we were concerned that the effects of PGE2 might be
restricted to certain splice forms. Nevertheless, results from an early experiment suggest otherwise. PGE2
increased the frequency of p53 mRNA+ cells regardless of whether PCR amplification involved primers
spanning p53 exons 2–4 (region A), the 3′ end of exon 4 through the 5′ end of exon 7 (region B), or exons
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC3898655/?report=printable
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6–11 (region C). Within this experiment, ratios for frequency of p53+ cells with or without added PGE2
using primers for regions A, B, and C were 1.8, 4.0, and 2.0, respectively.
Single-cell RT-PCR reveals p53 mutations within occasional progeny of a TI response to
BCR:CD21-L, IL-4, and BAFF
The prospect that elevated p53 transcription during a period of active replication and high AID expression
might foster p53 mutations led us to sequence the purified p53 amplicons from each positive lymphoblast.
We focused on upstream exons 2 through 4 because AID-induced mutations are more frequent near
transcription start sites (60). This screen revealed p53 mutations, but only in the progeny of 2 of 6
experimental cultures, each involving distinct B-cell donors (Table 1). The total frequency of p53
mutations in cultures with or without exogenous PGE2 (average of 6.2×10−4 mutations/bp sequenced) was
greater than an estimated background amplification error rate of <0.8 × 10−4/bp in our assays (Table 1).
Somewhat surprisingly, when divided progeny of PGE2-pulsed and control cultures were compared for
p53 mutations, we found no evidence that p53 mutations were more frequent in cultures pulsed with PGE2
(Table 1, columns 11–14). This was noted on the basis of mutations per total p53 mRNA+ cells sequenced
(5/15 vs. 7/51 for nonpulsed vs. PGE2-pulsed cultures, respectively) as well as mutations per total cells
under study (Table 1, columns 13, 14).
There is a plausible reason why PGE2-pulsed cultures did not reveal heightened p53 mutagenesis despite
the concomitant elevation in AID protein and p53 transcription. Cells with PGE2-promoted DNA
alterations (including p53 mutations) might have been excluded from analysis due to prior DNA damageinduced death. The data in Fig. 8 support this explanation. Notably, viable-gated blasts of PGE2-pulsed
cultures expressed higher pH2AX (a measure of DNA double-strand breaks; ref. 24) than did control
blasts, but only in the presence of pan-caspase inhibitor Z-VAD. This reinforces past suggestions that
PGE2 promotes DNA damage in TI-activated B lymphoblasts (35) and shows that those with DNA
double-strand breaks are prone to death. Thus, if p53-mutated cells were enriched in the subset with high
levels of DNA damage, they would have been deleted, unless, of course, the mutation promoted survival.
Next, we closely examined the type of p53 mutations in these TI cultures, both as a whole and with or
without supplementary PGE2. Although numbers were limited, as seen in Table 2, a majority of the total
mutations are missense, resulting in amino acid changes. These include changes in proline and cytosine
that could alter protein structure. In addition, transition mutations (83% of total) significantly outnumber
transversions under all conditions (Fig. 9 and Table 3; P=0.04). Both the latter finding and several
characteristics concerning mutation location and type are consistent with a role for AID in p53
mutagenesis within TI-activated clones. First, the majority of p53 mutations are localized at cytosine (C)
or guanine (G) residues (50% for mutated cells in experiment 3 and 83% for mutated cells in experiment 6;
average=67%; Fig. 9A). Nevertheless, when corrected for total C or G sites available for mutation, this
difference is not statistically significant (P=0.48). Due to a high GC/AT ratio in this region, the fraction of
mutations per total C/G sites and per total A/T sites is 0.00097 and 0.00082, respectively. Second, AIDcharacteristic C → T and G → A transition mutations that can represent direct replication of a U:G lesion
(61,–63) are frequently observed: in experiment 6 (T597), 75% of total were C → T; in experiment 3
(T612), 33% of total were G → A. Third, the C → A transversion, which can occur on uracil DNA
glycosylase (UNG) excision of U and replication of the resulting abasic site (62, 63) represents 17% of the
total mutations. Fourth, all of the A/T mutations (2 A→G and 1 T→C in experiment 3; 1 T→C in
experiment 6) are noted proximal to a C/G. These are consistent with the recognition of an AID-induced
U:G lesion by an atypical mismatch repair (MMR) pathway and resulting DNA polymerase-dependent
A/T mutation (63,–65). Interestingly, PGE2-pulsed cultures have a statistically lower frequency of C/Gtargeted mutations (P=0.018; Table 3) and favor A/T-targeted mutations (Fig. 9), albeit the latter bias is not
of statistical significance (Fig. 9A and Table 3). A final attribute suggesting AID activity (66) is that
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC3898655/?report=printable
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several cells had >1 mutation (Fig. 9). Of the 4 mutated cells in PGE2-pulsed cultures, 50% had multiple
mutations in exon 4: 1 had 3 mutations (in residues 365, 458, and 497), and the other had 2 mutations (in
residues 462 and 483). Of the 4 mutated cells in nonpulsed cultures, only 1 (25%) had multiple mutations
(in residues 363 and 442). Nevertheless, due to insufficient statistical power, no conclusions could be
drawn concerning the effects of supplementary PGE2 on multiplicity of mutations.
Also, some attributes incompatible with AID involvement were observed. First, the observed C/G targeted
changes were not found at the C/G residues in RGYW/WRCY motifs known to be AID hot spots (refs. 8,
61, 67; Fig. 9A; and Table 3). One mutation (A→G at residue 458) was detected in the W residue of a
WRCY motif, however. The latter occurred in a PGE2-pulsed B cell. Second, 3 of 4 C → T mutations
found in exon 4 within experiment 6 localized at AID cold spots, SYC/GRS, in which S = G or C and Y =
pyrimidine (C/T; ref. 61; Fig. 9A, B; and Table 3). Nevertheless, when the probability of targeting a cold
spot over a hot spot in all sequenced cells was examined by considering the total available sites of each (42
cold spots and 17 hot spots within each commonly sequenced 199-nt span), there was no statistical
difference (P=0.31). Mutations in cold spots are more consistent with the mutagenic activity of ROS,
which often induces C → T transitions (68). Thus, a combination of AID-driven and non-AID (possibly
ROS)-driven processes appear to be present in these TI-activated B lymphoblasts.
An intriguing finding emerged through sequencing cDNA of single cells through p53-specific RT-PCR. In
several instances, both a major peak representing the p53 mutated residue and a minor peak representing
the wild-type residue were observed within the same sequence chromatograms (Fig. 9B, cells designated
by asterisk), and the possible implications of their presence are discussed below.

DISCUSSION

Go to:

The p53 gene is a relatively rare candidate for p53 mutation during TD B-cell GC responses due in part to
strong repression of p53 gene transcription by Bcl-6 (2). Nevertheless, results from the present study
suggest that this is not the case for B-cell clonal expansion elicited by TI stimuli. Within dividing
lymphoblasts elicited by TI stimuli typical of inflamed tissues (14,–21), the p53 gene is transcriptionally
active. Furthermore, sequencing of p53 RT-PCR amplicons from single blasts shows that p53 mutations
arise at a relatively high overall frequency, average of ∼6.2 × 10−4 mutations per sequenced base pair. This
is similar to that in human peripheral blood mononuclear cells (PBMCs) exposed to UV-irradiated hepatitis
C virus, 4.6 × 10−4 mutations/bp (69), but significantly greater than in normal PBMC, 0.3 × 10−4
mutations/bp (69), and in mouse Peyer's patch GC B cells, 0.08 × 10−4 mutations/bp (8).
While the average p53 mutation rate was derived from experiments with 6 separate B-cell donors, the
mutations were concentrated in the lymphoblasts of only 2 donors. Thus, the average underrepresents the
mutation frequency in certain activated B-cell cultures: range of 12–48 × 10−4 mutations/bp. The reason
for the variation between donors is unknown, but might involve donor epigenetic or genetic variability
influencing AID activation, level of generated ROS, and/or DNA-repair enzymes. Notably, this variation
does not reflect differences in the frequency of single cells scoring as p53 mRNA+. In addition, it does not
reflect degree of activation, since the proliferative responses to C3d-Ag, IL-4, and BAFF were comparable
in all experiments (data not shown). In addition, it seems highly unlikely that the replicating blasts with
p53 mutations represented preacquired mutations in the original resting B cells. We base this on the
following points: the enrichment procedure yields cells that are ≥97% IgD+ and IgM+, the strong
proliferative response requires signaling via IgM (36), and no mutation was observed more than once in a
given donor. Finally, it is improbable that mutations in 2/6 of the B-cell cultures represent errors during
cDNA preparation or p53 amplification. The conditions for cDNA preparation and p53 RT-PCR
amplification were uniform. Most notably, significant differences in mutation incidence were noted in
cultures of 2 donors (T587 and T597) that were simultaneously processed for cDNA preparation, p53 RT-
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PCR amplification, and sequencing. Rather, our collective findings suggest that p53 mutations are more
apt to develop in some backgrounds than others during this TI response.
The p53 mutations observed had characteristics consistent with either AID or ROS activity: transitions >
transversions, with many transitions representing C → T. In support of AID function are the strong
expression of AID in replicating blasts, seen here and previously (35); the targeting of all mutations to
either C/G or to A/T proximal to C (consistent with replication of a AID-introduced U:G lesion or activity
of an error-prone MMR-like pathway, respectively; refs. 62, 63, 70,–72); and the discovery that several
cells had 2 or 3 p53 mutations within a relatively short span of DNA, characteristic of the “processive”
function of AID (66). Nevertheless, in 1 donor, C → T nucleotide changes were evidenced in AID cold
spots, more compatible with ROS activity. Thus, these experiments could not attribute the expressed
mutations to solely AID and suggest that multiple mechanisms are involved.
Of interest, the sequence chromatograms of several mutated cells revealed 2 mutated nucleotides per
residue: the major mutated nucleotide and a more minor peak of the wild-type nucleotide. We suspect the
latter may have originated from residual wild-type mRNA in the mutant cell. This explanation is consistent
with recent mutation during the proliferative burst and the ∼8 h half-life of p53 mRNA in these cells. It
appears less likely that the presence of both mutant and wild-type residues represents mRNA from the 2
p53 alleles of a single cell: one mutated and the other not. Of pertinence, single-cell RT-PCR of cultures
from donors heterozygous for the common p53 codon 72 C → G single nucleotide polymorphism (SNP)
show that allelic exclusion is prominent in these activated blasts: a single cell expressed either the p53-72C
SNP or the p53-72G SNP, but not both (unpublished results). While the mutant and original p53 residue
appeared to be commonly observed in cells bearing 1 mutation, in the case of 2 of 3 cells bearing multiple
mutations, coexpression was suggested only for the most downstream mutation (Fig. 9B). This finding is
consistent with sequential mutations being acquired during differing division cycles (66, 73). In 1 of 3
multiply mutated cells, mutant and original alleles were expressed in both mutated p53 residues,
suggesting that the cell rapidly acquired these mutations within the same division cycle. It might be
relevant that this cell (D5) derived from a culture receiving AID-up-regulating supplementary PGE2 (
Fig. 9B and ref. 35).
A novel and potentially quite important finding of this study was that that PGE2, produced at low levels by
activated B cells and in higher amounts by other inflammatory cells, significantly augments p53 mRNA
transcription in activated blasts. This was demonstrated through a series of experiments involving the RNA
polymerase inhibitor actinomycin D. To our knowledge, there is no prior evidence of PGE2-modulated p53
gene transcription, albeit PGE2 is reported to prolong the half-life of p53 protein through serine-15
phosphorylation (74). Mice globally overexpressing COX-2 during embryogenesis exhibit a prostaglandinmediated, tissue-specific rise in p53 protein that occurs independently of p53 serine 15 phosphorylation
(49). Whether the increased p53 protein represented elevated p53 gene transcription was not examined.
Interestingly, within activated d 4–5 cultures, only the replicating blasts responded with increased p53
mRNA synthesis to PGE2. Similar augmenting effects of the selective agonist butaprost have implicated
the cAMP-elevating EP2 receptor.. Our earlier findings that EP2 levels correlate directly with the
frequency of divisions (35) provides a likely explanation for why the divided blasts appear to be more
receptive to PGE2 signaling.
Notably, there was no statistically sound evidence that cells with PGE2-augmented p53 gene transcription
had a greater frequency of p53 mutations. Nevertheless, findings of elevated DNA double-strand breaks in
cultures pulsed with PGE2 (when a pan-caspase inhibitor was added to block cell death) suggest an
explanation. At the time of viable lymphoblast sorting for single-cell RT-PCR and sequencing, many cells
experiencing PGE2-promoted DNA changes (including p53 mutations) may have been omitted from
analysis due to their recent death. In an effort to better understand whether PGE2 signaling promotes p53
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC3898655/?report=printable
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mutagenesis in the absence of T-cell-dependent high-fidelity DNA repair (37), future studies will involve
additional steps to more effectively block the activation-induced death characteristic of these TI clones.
The downstream mechanisms for PGE2-boosted p53 gene transcription are presently unclear, but there are
several options to consider. The human p53 basal promoter upstream of exon 1 has an NF-kB motif that
binds p50 and p65, as well as sites for AP-1 and Myc/Max (58, 75, 76) and is reported to be transactivated
by PKCδ, in combination with Btf (77, 78). In mice, a site upstream of the basal promoter mediates
c/EBPβ-regulated p53 transcription (79). Notably, there is evidence that cAMP regulates most of the above
transcription factors (80,–88). PGE2 might also influence p53 gene transcription in an epigenetic manner
through methylation, given that cAMP-up-regulating PGE2 receptors, EP2 and EP4, regulate the
expression of DNA methyl transferases (89, 90).
The above study probed for p53 gene mutations in upstream exons 2–4 on the basis of their proximity to
the transcriptional start site, which should favor targeting by AID (60). However, mutations in this region
are uncommon in malignancies, even within the B-cell lineage, and mutations in downstream exons
encoding the DNA-binding domain are highly favored (9, 91,–94). Nonetheless, exon 4 appears targeted
for mutation in soft-tissue sarcomas (95), and occasional exon 4 mutations have been reported in B-CLL
and high-grade non-Hodgkin's B-cell lymphomas (96, 97). While the exon 4 missense mutations revealed
in this study may not be transforming, they may be functionally relevant. First, the proline-rich exon 4
domain promotes p53 interactions with other cell proteins (98,–100). Second, exon 4 is important for
transcription-independent p53-apoptosis, albeit not cell cycle block (101,–103). Third, the common p53
exon 4 SNP in humans, which encodes Pro vs. Arg at codon 72, can significantly alter p53 function (104,–
108). Finally, the p53 molecule has a multitude of roles that extend beyond the regulation of cell cycle
turnover and apoptosis (104, 109,–114). Thus, p53 mutations that do not advance malignancy might,
nevertheless, affect other B cell roles, e.g., in regulating inflammation.
In sum, when assimilated with prior observations, this study's novel findings have important implications
for the process of p53 mutagenesis in vivo. They suggest that when recirculating naive B cells encounter
the above synergistic TI stimuli within inflamed tissues, a short burst of proliferation will ensue. This will
generate lymphoblasts expressing several COX-2 axis proteins (COX-2, mPGES-1, and EP2). Together
with supplementary PGE2 from nearby inflammatory cells, this can promote expression of DNAmodifying AID (35), heighten p53 gene transcription (this study), and provide positive feedback signaling
for elevated COX-2 and EP2 expression (refs. 35, 115 and unpublished results). Notably, if antigenspecific T-cell help is lacking, blasts will be deficient in p53-repressive Bcl-6 (2) and high-fidelity DNA
repair enzymes (37). Together, these factors should significantly increase the likelihood that p53 mutations
develop and are retained. While only a minority of the induced p53 mutations may be functionally
relevant, those with a positive influence on cell survival and growth may undergo positive selection. This
is particularly so given the high propensity of TI clones to succumb to p53-driven activation-induced cell
death (24, 34, 36). Furthermore, the observations that p53 mutations in nontransformed synovial
fibroblasts of rheumatoid arthritis patients are linked to elevated IL-6 production (116) suggest that
occasional p53 mutations might promote the proinflammatory properties of B cells.
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AID activation-induced cytosine deaminase
B-CLL B-cell chronic lymphocytic leukemia
BCR B-cell antigen receptor
CFSE carboxyfluorescein succinimidyl ester
COX-2 cyclooxygenase
FO follicular
GC germinal center
MZ marginal zone
PBMC peripheral blood mononuclear cell
qPCR quantitative PCR
ROS reactive oxygen species
SNP single nucleotide polymorphism
TD T-cell dependent
TI T-cell independent
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Figure 1.

p53 protein is maximally up-regulated at earlier divisions than is AID protein. p53 and AID were simultaneously
evaluated in CFSE-labeled B-cell cultures proliferating in response to BCR:CD21-L, IL-4, and BAFF. A) Representative
experiment in which CFSE-labeled cells were stained intracellularly for AID or p53 on d 4.5 after activation. Top panel:
gating of CFSE-labeled cells for divisions. Bottom panel: PE fluorescence within division-gated cells stained for AID or
p53 (dark lines) or respective isotype control (dotted lines). B) Pooled data from 6 experiments in which p53 and AID
were simultaneously evaluated. Top panel: data are expressed as ratio mean fluorescence intensity (RMFI) = ratio of the
MFI of p53 or AID stained cells vs. MFI of control stained cells. Bottom panel: RMFI values from each experiment were
computed as percentage of the maximal RMFI observed within all assessed divisions.

https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC3898655/?report=printable

20/32

5/25/2018

Effects of prostaglandin E2 on p53 mRNA transcription and p53 mutagenesis during T-cell-independent human B-cell clonal expansion

Figure 2.

B cells replicating in response to BCR:CD21-L, IL-4, and BAFF exhibit elevated levels of p53 mRNA. A)
Semiquantitative RT-PCR analysis of p53 mRNA levels in resting B cells and activated d 4 cultures stimulated with
BCR:CD21-L, IL-4, and BAFF. Values represent ratios of densitometric intensity in the p53 and β-actin bands B) qPCR
assessment of p53 mRNA in resting B cells vs. d 4 blasts. ΔCt values for p53 were obtained by comparisons with β-actin.
Values for fold difference (Δ) were obtained by comparing ΔCt values in activated cultures with the ΔCt values of B cells
prior to activation. P value shows that the differences between Δ values in resting vs. activated cells in a total of 4
replicate experiments were of borderline significance, using a 2-tailed paired Student's t test. C) Undivided blasts and
divided blasts within activated cultures were sorted on the basis of CFSE fluorescence. Left panel: representative
experiment. Right panel: results for p53-specific q-RT-PCR of isolated RNA. Divided blasts express significantly more
p53 mRNA than do undivided blasts within the same cultures (P=0.006; 2-tailed, paired Student's t test).
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Figure 3.

PGE2 augments p53 mRNA expression during TI clonal expansion. A) B-cell cultures activated with BCR:CD21-L, IL-4,
and BAFF were pulsed with exogenous PGE2 (50 nM) or ethanol vehicle alone on d 4; mRNA was isolated at varying
periods after the pulse. qPCR of cDNA was used to measure the levels of p53 mRNA in PGE2-pulsed and control
cultures. Values for fold difference (Δ) were obtained by comparing ΔCt values in PGE2-pulsed cultures with the
respective ΔCt values in vehicle-pulsed cultures at the same time point. Dotted line represents a value of Δ = 1 for each of
the vehicle control cultures. Results are the mean ± SE Δ fold difference in 3 separate experiments, where P represents
significance of differences between Δ values in PGE2-pulsed vs. vehicle-pulsed cultures. B) Pooled results from a total of
6 experiments which evaluated p53 mRNA levels in cultures activated as in A with/without an 8 h pulse of PGE2 on d 4.
C) Day 4 activated cultures of CFSE-labeled cells with or without pulse of exogenous PGE2 8 h earlier were harvested
and sorted on the basis of their division status: undivided vs. divided (3–4 divisions). qPCR of cDNA with p53 and β-actin
probes was used to monitor p53 mRNA levels, as in Fig. 2. Values for Δ in each sorted population were obtained by
comparing ΔCt values in cells from PGE2-pulsed vs. unpulsed cultures. P values show that a pulse with PGE2
significantly augments p53 mRNA levels in the divided blasts (P=0.007) without affecting p53 levels in the undivided
cells (P=0.51; 2-tailed, paired Student's t test).

https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC3898655/?report=printable

22/32

5/25/2018

Effects of prostaglandin E2 on p53 mRNA transcription and p53 mutagenesis during T-cell-independent human B-cell clonal expansion

Figure 4.

Selective agonist for EP2, a PGE2 receptor up-regulated during division, promotes heightened p53 mRNA. A) EP2
receptor expression is preferentially elevated with replicating B lymphoblasts in cultures activated by BCR:CD21-L, IL-4,
and BAFF. Expression of each of 4 PGE2 receptors on B cells was assessed with receptor-specific Abs, as described
elsewhere (35). EP receptor density expressed as PE fluorescence; division number revealed by CFSE fluorescence. B)
p53 mRNA-up-regulating effects of an EP2 receptor-specific agonist, butaprost. Levels of p53 mRNA in activated
cultures exposed on d 4 to butaprost (or ethanol vehicle) were assessed at varying intervals after the pulse. qPCR fold Δ
values from experiments with a common harvest interval following the pulse were pooled and expressed as means ± SE. P
values indicate that the level of p53 mRNA in butaprost-pulsed cultures is significantly different from that in controlpulsed cultures. C) Dose response of the p53 mRNA-up-regulating effects of butaprost (single experiment with all doses
tested).
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Figure 5.

Inhibition of RNA polymerase down-regulates baseline p53 mRNA and blocks PGE2-promoted increases in p53 mRNA.
B cells were activated with BCR:CD21-L, IL-4 and BAFF. After d 4 of culture, 1 set of replicate cultures received a pulse
with 5 μM actinomycin D (42), while another set received vehicle alone. After a period of 15 min, a subset of each of the
above were subsequently pulsed with PGE2 (50 nM) or vehicle alone and cultured for an additional 8 h. Cultures were
harvested, RNA was isolated, cDNA was prepared, and levels of p53 transcript were assessed by qPCR. Mean ± SE fold Δ
values are shown as in Fig. 2, for a total of 4 experiments.
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Figure 6.

PGE2-promoted rise in p53 mRNA is not explained by PGE2-induced mRNA stabilization. In order to assess whether p53
mRNA stability was affected by a pulse of exogenous PGE2, sets of replicate cultures were pulsed with PGE2 (50 nM) or
vehicle alone. After 8 h of additional culture (for peak PGE2-induced elevation in p53 mRNA; Fig. 3), a series of
replicates within each of the above subsets received actinomycin C (5 μM) or DMSO vehicle. RNA was isolated at
varying time points after the actinomycin D or DMSO (0.5, 1, 3, 8, and 20 h). q-PCR of cDNA measured p53 transcript
levels in each culture, expressed as a fraction of that present in the respective PGE2-untreated or PGE2-treated cultures
with DMSO vehicle (means±SE of 4 experiments). Dotted line represents the normalized level of transcript present in
cultures with or without PGE2 but without actinomycin D. Data were statistically analyzed (see Materials and Methods) to
compare mean fold change of p53 mRNA between PGE2-pulsed and nonpulsed cultures to their respective controls across
time after actinomycin D. There was no significant interaction between time and presence of PGE2 (P<0.72), indicating
that the slope of p53 mRNA expression after actinomycin D (mRNA decay) was not significantly different with or
without PGE2. Nevertheless, when the interaction term was removed from the model, the main effects of cell type and
time were significant. Cells without PGE2 supplement had a significantly greater p53 mRNA, relative to their controls, as
compared to those pulsed with PGE2 (P<0.0001). Overall, p53 mRNA expression decreased over time for all cells relative
to controls (P<0.0002). Taken together, these experiments show that the elevated p53 mRNA levels in PGE2-prepulsed
cultures do not reflect diminished degradation of the p53 transcript.
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Figure 7.

Single-cell RT-PCR shows that PGE2 augments the frequency of cells with detectable p53 mRNA. A) Single-cell RT-PCR
was performed with sorted CFSE-labeled lymphoblasts (representing 3–4 divisions) from d 5 activated cultures (or d 6 for
1 experiment) with or without exogenous PGE2 (50 nM) on d 2 and 4. Shown are amplicons of β-actin and p53 from a
total of 56 single cells analyzed from cultures with or without PGE2 supplement. While most wells with a single sorted
cell were positive for β-actin mRNA, notably fewer were positive for p53 mRNA. B) Data from 6 separate experiments,
each evaluating the frequency of p53 mRNA+ cells, as above. Below each set of bars, representing frequency of p53+
single cells within the sorted dividing population in cultures with or without PGE2, are the absolute values for number of
p53 mRNA+ cells per total cells analyzed. (Note that in experiments T613, T612, T587, and T597, all cultures received a
Z-VAD pulse on d 3.5 following activation; experiments T602 and T606 did not). C) Summarized data from the pooled
experiments in B were subjected to statistical evaluation using a 2 × 2 contingency table and Fisher's exact test. The
difference in frequency of p53 mRNA+ cells within sampled individual cells of cultures exposed/not exposed to
exogenous PGE2 was highly significant (2-sided P<0.0001).
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Table 1.
Analysis of p53 mutation frequency in progeny of TI B-cell clones stimulated by BCR:CD21-L, IL4, and BAFF with or without supplementary PGE2
Experiment
Experiment

Donor
Donor B
B
cells
cells a
cultured
cultured

Total
Total cells
cells
screened
screened

Total
Total cells
cells p53
p53
seq+
seq+

Total
Total
nucleotides
nucleotides
b
screened
screened

Total
Total
mutations
mutations
detected
detected

Mutation
Mutation
frequency/base
fr
frequency/base
fr
c
pair
pair

No
No +PGE
+PGE2 No
No +PGE
+PGE2 No
No +PGE
+PGE2 No
No +PGE
+PGE2 No
No +PGE
+PGE2 N
N
pulse
pulse
pulse
pulse
pulse
p
pulse
pulse
pulse
pulse
pulse
p
1

T602

28

28

4

9

1320

2970

0

0

0

0

0

2

T606

90

90

1

5

330

1650

0

0

0

0

0

3

T612

90

90

3

10

990

3300

2

4

20 × 12 ×
−4
−4
10
10

0.

4

T613

90

90

0

13

0

4290

0

0

0

0

0

5

T587

12

12

4

8

840

1680

0

0

0

0

0

6

T597

12

12

3

6

630

1260

3

3

48 × 24 ×
−4
−4
10
10

0.

322

322

15

51

4110

15,150

5

7

12 × 5 ×
e
−4
−4
10
10

0.

Total

a

Based on our prior findings that PGE2 can have both prosurvival and proapoptotic functions on B lymphoblasts, in
part dependent on PGE2 dose (34), cultures were monitored for viability during sorting of PGE2-pulsed/nonpulsed
single cells for p53-specific RT-PCR. Percentage viability in the d 5 cultures (excepting T612 on d 6) at time of
sorting was T602 = 67/74% with/without PGE2, respectively; and similarly, T606 = 72/73%; T612 = 36/40%; T613 =
58/60%; T587 = 64/63%; T597 = 65/68% [mean of 60±5 vs. 63±5% viability in PGE2− and PGE2+ cultures,
respectively; P=0.06 (nonsignificant)]. There is a high likelihood that PGE2 prosurvival effects were minimized due
to the relatively high cell density of the 24-well cultures from which the sorted cells originated (106 cells/2 ml).
Notably, other analyses involving cells cultured at varying densities (0.01–0.4×106 cells/0.2 ml in 96-well plates)
show that supplementary PGE2 boosts lymphoblast viability only in cultures of low to moderate cell density
(unpublished results). This may reflect sufficient levels of autocrine PGE2 at higher cell density. It is also possible
that at the higher culture density, prosurvival effects of PGE2 on one subset of dividing blasts are masked by opposing
proapoptotic effects on another subset. Consistent with the latter, viable cells with PGE2-up-regulated levels of
phospho-H2AX are prominent only when cultures are pulsed with the pan-caspase inhibitor Z-VAD (see Fig. 8). In an
effort to reduce cell death, cultures T612, T613, T587, and T597 received Z-VAD (40 μm) on d 3.5–4 following
activation. Nevertheless, as compared to previously noted significant prosurvival effects of Z-VAD in less dense
cultures (within 96-well plates; ref. 24), significant apoptosis remained. The less-than-expected Z-VAD function
might reflect limited Z-VAD infiltration into the substantially larger clusters of activated cells present in the 24-well
cultures seeded with 106 cells, a need for counteracting caspase function at an earlier interval in these cultures, or
alternatively, activation of non-caspase-mediated death.
b
In experiments 1–4, single-cell amplicons from cDNA were generated using primers for exon 2 and exon 4 (400-bp
amplicon), whereas in experiments 5 and 6, amplicons were generated using primers for exon 4 alone (280-bp
amplicon; 199 bp were common to both). In sequencing these amplicons, the most 5′ nucleotides were not considered
due to sequence noise near the binding region for the sequencing primer.
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c

Determining the background rate of p53 mutation in unstimulated cells is not possible due to insufficient recovery of
p53 mRNA for this single-cell assay. Nevertheless, a background rate based on the frequency of introduced mutations
from 2× PCR amplification of the p53 exon segment from cDNA and 1× amplification for sequencing was assessed
by calculating the total nucleotides sequenced in the 4 of 6 experiments that exhibited no p53 mutations. This
indicates that background error rate is <0.8 × 10−4/bp.
d
In an effort to avoid the bias of calculating mutation frequency on the basis of only cells with high detectable levels
of p53 mRNA, values for mutation frequency per number of single cells screened were determined. While this
assessment is compromised by the fact that most cells screened did not display sufficient p53 mRNA for evaluation,
the calculated frequencies might be more reliable given that it is highly likely that those cells with low p53 mRNA
transcription are unlikely candidates for mutation.
e
There was no significant association between the frequency distribution of mutations (per base pair) and culture
(PGE2+ vs. PGE2−); P < 0.15 by Fisher's exact test. In addition, there was no significant association between the
frequency of mutations (per cell) and culture (PGE2+ vs. PGE2−); P < 0.56 by χ2 analysis.
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Figure 8.

Divided progeny from PGE2-pulsed cultures manifested higher pH2AX staining (indicative of DNA double-strand
breaks) when cultures were treated with pan-caspase inhibitor, Z-VAD. CFSE-labeled B cells were activated in 96-well
plates (105 cells/200 μl), and activated cultures received PGE2 (50 nM), as indicated, on d 2 and 4 and 40 μM Z-VAD (or
DMSO vehicle) on d 4. On d 5, cultures were harvested, fixed, and stained intracellularly with PE-anti-pH2AX (or PEIgG control). PE MFI was determined for cells whose light scatter and CFSE fluorescence represented the viable, divided
subset prior to fixation. A) Numbers represent the RMFI (ratio of pH2AX MFI/MFI IgG control MFI). B) Bars represent
the ratio of the RMFI in PGE2-supplemented cultures/RMFI in nonsupplemented cultures of 2 experiments.
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Table 2.
Frequency of codon 4 missense p53 gene mutations in TI-activated human B cells
Mutated B cell

PGE2 pulse Total Silent Missense

Location

T612, experiment 3
Cell A

No

2

0

2

Codon 56 (E→K); codon 82 (P→Q)

Cell B

Yes

1

1

0

Cell C

Yes

3

2

1

B3-cell A No

1

1

0

B4-cell B No

1

1

0

B5-cell C No

1

0

1

b
Codon 72 (R→C)

D2-cell D Yes

1

0

1

Codon 75 (P→L)

a
Codon 96 (S→P)

T597, experiment 6

a
D5-cell
codon 96 (S→P)
Mutated B
cell E Yes
PGE pulse 2Total 0Silent 2Missense Codon 89 (P→T);
Location

a

The codon 96 S→P missense mutation was observed twice, in PGE2-pulsed cells of 2 distinct donors, from differing
experiments. This mutation occurred in a MHT motif, which can be targeted during the secondary phase of AIDdriven mutagenesis (65).
b
This mutation occurred in exon 4 codon 72, the site of a common functionally relevant SNP in humans. This cell
reverted from expression of codon 72-Arg to codon 72-Cys.

https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC3898655/?report=printable

30/32

5/25/2018

Effects of prostaglandin E2 on p53 mRNA transcription and p53 mutagenesis during T-cell-independent human B-cell clonal expansion

Figure 9.

p53 mutations are present within dividing lymphoblasts of a TI response to BCR:CD21-L, IL-4, and BAFF with or
withouth supplementary PGE2. A) p53 amplicons from experiments in Fig. 7 were sequenced (see Materials and
Methods). Shown are sequenced segments with identified mutations from 8 distinct cells from 2 donors, as well as the
corresponding germline p53 sequence (numerical positions represent residues of germline DNA beginning at the
transcriptional start site). Transition mutations are in red; transversion mutations are in green. B) Segments of forward
(FOR) and reverse (REV) p53 sequence chromatograms indicating the mutations detected per individual cell. Arrows
indicate mutated residues. Asterisks indicate cells in which both the mutation (predominantly expressed) and the original
wild-type sequence (minor) were coexpressed. Coexpression was validated by similar results on sequencing in either
direction. C) Summarized data showing the percentage of total p53 sequence-positive single cells that expressed 1, 2, or 3
mutations/sequence. D) Normalized data from panel C, showing the percentage of total p53-mutated cells that expressed
1, 2, or 3 mutations/sequence. For both C and D, statistical power is too low to determine significance.
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Table 3.
Characterization of exon 4 p53 mutations in progeny of human B clones following TI activation
with/without supplementary PGE2
Mutation type

Mutations [sites (total possible sites)] Mutation frequency
No pulse

+PGE2

No pulse

+PGE2

P

At G

1 (705)

1 (2397)

0.00142

0.00042

At C

4 (1170)

2 (3978)

0.00342

0.00050

0.403
*
0.027

At A

0 (540)

2 (1836)

0

0.00109

1

At T

0 (570)

2 (1938)

0

0.00103

1

Sum: G/C

5 (1875)

3 (6375)

0.00267

0.00047

*
0.018

Sum: A/T

0 (1110)

4 (3774)

0

0.00106

0.580

Total transitions

4 (2985)

6 (10,149)

0.00134

0.00059

0.249

Total transversions

1 (2985)

1 (10,149)

0.00034

0.00010

0.403

2 (630)
a
Total RGYW/WRCY (hot spot) 0 (255)

2 (2142)

0.00460

0.00135

0.224

0 (867)

0

0

Total WA

0 (150)

1 (510)

0

0.00196

Total TW

0 (150)

0 (510)

0

0

a
Total SYC/GRS (cold spot)

a
Total MHT
Mutation type

NA
1
NA

0 (255)
2 (867)
0
0.00231 1
Mutations [sites (total possible sites)] Mutation frequency
P

Nofrom
pulsesingle cells of+PGE
pulse
+PGE
Comparative analysis of all p53 sequences
nonpulsed and No
PGE
cultures derived from 6
2-pulsed
diverse donors was performed with the web-based SHMTool (http://scb.aecom.yu.edu/shmtool). This permits
determinations of the frequency of various categories of somatic hypermutation on the basis of the base composition
and total potential sites of each category available for mutation. For the above comparisons, a stretch of 199 exon 4
p53 residues that were commonly sequenced in all experiments was used. While the low frequency of mutations did
not meet the minimal conditions for statistical reliability using the program's χ2 analysis, a separate statistical
comparison was made with Fisher's exact test.
a

Letter designations for alternate nucleotides: R = A/G; S = G/C; Y = C/T; W = A/T; M = A/C; H = A/C/T (61, 65).
P < 0.05 for mutation frequency in pulsed vs. nonpulsed cohort; Fisher's exact test.

*
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